日發精機(002520.SZ):五軸聯動機牀等複合設備將是公司未來重點發展方向之一
格隆匯11月27日丨日發精機(002520.SZ)於2023年11月24日接受特定對象調研,就“公司五軸聯動情況的介紹?”,公司表示,公司致力於研發高端數控機牀,擁有自主知識產權的核心技術,擁有多年的五軸聯動數控機牀技術沉澱與應用,也具備五軸聯動數控機牀的生產能力;公司全資子公司意大利MCM公司也致力於卧加領域開發,從四軸到五軸到銑車複合、銑車磨一體,核心部件MCM都能自主研發生產。五軸聯動機牀等複合設備將是公司未來重點發展方向之一,公司將會加大產品研發力度,積極開拓市場,提升經營業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.